You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK Alterations

Showing 1 - 25 of 2,679
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)

Active, not recruiting
  • Melanoma
  • Middletown, New Jersey
  • +3 more
Jan 25, 2022

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

Not yet recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Providence, Rhode Island
    Rhode Island Hospital, Brown University
Mar 2, 2023

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

Recruiting
  • Locally Advanced Solid Tumors
  • +3 more
  • Oral repotrectinib (TPX-0005)
  • Los Angeles, California
  • +27 more
Aug 9, 2022

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) Trial in Sunto-gun, Koto, Fukuoka (LDK378)

Completed
  • Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
  • Sunto-gun, Shizuoka, Japan
  • +2 more
Dec 16, 2020

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Korea, Republic of, United States (Entrectinib)

Completed
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Orange, California
  • +9 more
Jun 7, 2021

Solid Tumor, Haematological Malignancy, Malignant Tumor Trial in United Kingdom (Alectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory

Active, not recruiting
  • Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
  • +5 more
  • Crizotinib (PF-02341066)
  • Brussels, Belgium
  • +24 more
May 9, 2022

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC Trial in Worldwide (PF-06463922, Crizotinib)

Active, not recruiting
Has Results
  • ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
  • Fayetteville, Arkansas
  • +71 more
Feb 16, 2022

Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

Not yet recruiting
  • Stage IIIB(N2) Non-small Cell Lung Cancer
  • +3 more
  • Pembrolizumab 200 mg IV infusion
  • Beijing, Beijing, China
    Peking University
May 30, 2023

Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto

Recruiting
  • Malignant Solid Neoplasm
  • +26 more
  • Birmingham, Alabama
  • +121 more
Aug 24, 2022

Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)

Active, not recruiting
  • Hematologic Cancers
  • +2 more
  • Villejuif, Ile De France, France
    Gustave Roussy
Sep 5, 2022

Lung Cancer Trial in Brampton (Questionnaires)

Recruiting
  • Lung Cancer
  • Questionnaires
  • Brampton, Ontario, Canada
    Milena (Lynn) Vicente
Jun 17, 2022

Cancer Diagnostics: Blood Versus Tissue Molecular Profiling

Active, not recruiting
  • Non-small Cell Lung Cancer
  • GUARDANT360
  • Calgary, Alberta, Canada
  • +5 more
Oct 31, 2022

Anaplastic Lymphoma Kinase Gene Translocation, NSCLC Trial in Boston

Recruiting
  • Anaplastic Lymphoma Kinase Gene Translocation
  • Non-Small Cell Lung Cancer
    • Boston, Massachusetts
      Massachusetts General Hospital Cancer Center
    Jan 14, 2022

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

    Withdrawn
    • Non-Small Cell Lung Cancer
    • InVisionFirst-Lung ctDNA assay
    • Los Angeles, California
    • +2 more
    Sep 16, 2022

    Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

    Recruiting
    • Locally Advanced Lung Non-Small Cell Carcinoma
    • +9 more
    • Duarte, California
    • +4 more
    Aug 17, 2022

    Metastatic Lung Cancer Trial in France (InvisionFirst® molecular panel)

    Active, not recruiting
    • Metastatic Lung Cancer
    • InvisionFirst® molecular panel
    • Bayeux, France
    • +15 more
    Aug 22, 2022

    Neuroblastoma Precision Trial

    Active, not recruiting
    • Neuroblastoma
    • Gene panel sequencing of tumor specimens
    • Los Angeles, California
    • +10 more
    Feb 16, 2022

    Resistance-associated Mutations in Metastatic Lung Cancer

    Recruiting
    • Lung Cancer
    • Liquid biopsy
    • Monza, MB, Italy
      Fondazione IRCCS San Gerardo dei Tintori
    Oct 10, 2023

    Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

    Recruiting
    • Soft Tissue Sarcoma
    • +2 more
    • Blood and tumor samples
    • Clermont-Ferrand, France
    • +9 more
    Dec 8, 2021

    NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • (no location specified)
    Jan 18, 2023

    Neuroblastoma, Cancer Trial in Philadelphia (procedure, genetic, other, behavioral, drug)

    Terminated
    • Neuroblastoma
    • Cancer
    • Biopsy
    • +12 more
    • Philadelphia, Pennsylvania
      The Children's Hospital of Philadelphia
    Jan 31, 2023

    Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +44 more
    • Biopsy
    • +23 more
    • Birmingham, Alabama
    • +166 more
    Feb 2, 2023